Last reviewed · How we verify
SHP643
At a glance
| Generic name | SHP643 |
|---|---|
| Also known as | DX-2930 (formerly), Lanadelumab |
| Sponsor | Shire |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Survey of Lanadelumab in Participants With Hereditary Angioedema
- A Study of Lanadelumab (SHP643) in Chinese Participants With Hereditary Angioedema (HAE) (PHASE3)
- A Study of Long-Term Safety and Efficacy of Lanadelumab for Prevention of Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor (PHASE3)
- A Study of Lanadelumab in Teenagers and Adults to Prevent Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH) (PHASE3)
- Expanded Access for the Prevention of Acute Attacks of 1) Hereditary Angioedema (HAE) in Children and 2) Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH) in Teenagers and Adults
- Efficacy and Safety of Lanadelumab (SHP643) in Japanese Participants With Hereditary Angioedema (HAE) (PHASE3)
- A Study of Lanadelumab to Prevent Hereditary Angioedema (HAE) Attacks in Children (PHASE3)
- Long-term Safety and Efficacy Study of DX-2930 (SHP643) to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SHP643 CI brief — competitive landscape report
- SHP643 updates RSS · CI watch RSS
- Shire portfolio CI